Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

about

Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

P2860

Q47380976-4A8FBCBB-3E39-44C4-9116-453992527F52

P2860

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

Item

http://www.wikidata.org/entity/Q38789642

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

@en

type

Item

label

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

@en

prefLabel

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

@en

P1476

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

@en

P2093

André van Gossum

http://www.w3.org/2001/XMLSchema#string

Ann Gils

http://www.w3.org/2001/XMLSchema#string

Anneline Cremer

http://www.w3.org/2001/XMLSchema#string

Charlotte Minsart

http://www.w3.org/2001/XMLSchema#string

Claire Liefferinckx

http://www.w3.org/2001/XMLSchema#string

Denis Franchimont

http://www.w3.org/2001/XMLSchema#string

Eric Quertinmont

http://www.w3.org/2001/XMLSchema#string

Jacques Devière

http://www.w3.org/2001/XMLSchema#string

Jean-François Toubeau

http://www.w3.org/2001/XMLSchema#string

Leila Amininejad

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab for induction and maintenance therapy for ulcerative colitis

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.

Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.

Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease.

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.

Optimizing anti-TNF treatments in inflammatory bowel disease.

Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.

Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.

P304

1371-1381

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MIB.0000000000001120

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28498153

http://www.w3.org/2001/XMLSchema#string

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

about

P2860

P2860

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698